M
Malcolm J. Moore
Researcher at Princess Margaret Cancer Centre
Publications - 238
Citations - 45832
Malcolm J. Moore is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Gemcitabine & Cancer. The author has an hindex of 64, co-authored 231 publications receiving 42222 citations. Previous affiliations of Malcolm J. Moore include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib.
Suzanne Richter,Jo-An Seah,Gregory R. Pond,Hui K Gan,Mary J. MacKenzie,Sebastien J. Hotte,Som D. Mukherjee,Nevin Murray,Christian Kollmannsberger,Daniel Heng,Masoom A. Haider,Robert Halford,S. Percy Ivy,Malcolm J. Moore,Srikala S. Sridhar +14 more
TL;DR: PFS with sequential TKIs was similar to observed and published results for any second-line therapy, and prior toxicity affected treatment patterns and the frequent use of at least 3 lines of therapy underscores the need for prospective sequencing trials in this disease.
Journal ArticleDOI
Novel targets in prostate cancer.
TL;DR: A discussion of a new method for quantification of the androgen receptor; the impact of high-dose vitamin D plus chemotherapy on hormone refractory disease and on the risk of thromboembolic disease; and the paradoxical effects seen with the raf-kinase and vascular endothelial growth factor inhibitor sorafenib.
Journal ArticleDOI
Outcome and toxicity of postoperative short course adjuvant radiation and chemotherapy following resection of adenocarcinoma of the rectum.
James D. Brierley,Neil D'Souza,Bernard Cummings,Jolie Ringash,J.-H. John Kim,Pamela Catton,Rebecca Wong,Malcolm J. Moore,Melania Pintilie,C. Shun Wong +9 more
TL;DR: Although treatment was well tolerated, the local relapse rate observed was high and further studies are required to determine the merits or otherwise of postoperative Short Course Adjuvant Radiation.
Journal ArticleDOI
A prospective economic analysis of cost-effectiveness of cetuximab for metastatic colorectal cancer patients from the NCIC CTG and AGITG CO.17 trial
Nicole Mittmann,Heather-Jane Au,Dongsheng Tu,Christopher J. O'Callaghan,Chris Karapetis,Malcolm J. Moore,John Zalcberg,John Simes,William K. Evans,Derek J. Jonker +9 more
TL;DR: This study is the first intergroup (Canadian/Australian) trial, that prospectively collected resource utilization and utility data for cetuximab vs. best supportive care a...
Journal ArticleDOI
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination with metronomic cyclophosphamide (mC) in advanced neuroendocrine tumors (aNET)
M. A. Quintela-Fandino,A. Young,Sheila Webster,M. Grewal,Lisa Wang,Malcolm J. Moore,Monika K. Krzyzanowska,T. W. Mak,Lillian L. Siu +8 more
TL;DR: In this article, a dynamic flow-coding approach was proposed for guiding individual OBDT. But the method is limited to static tissues, and there is a paucity of reliable PD assays for guiding OBDTs.